Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | NT5E | P21589 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ALB | P02768 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | AHCY | P23526 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | PNP | P00491 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22862138 | 1.00 | LMNA (0.58) | LMNANT5EHIF1AALDH1A1ALB | |
| SCHEMBL3054167 | 1.00 | LMNA (0.58) | LMNANT5EHIF1AALDH1A1ALB | |
| SCHEMBL3047081 | 0.90 | LMNA (0.50) | LMNANT5EHIF1AALDH1A1ALB | |
| SCHEMBL25712959 | 0.88 | LMNA (0.59) | LMNANT5EHIF1AALDH1A1ALB | |
| SCHEMBL3239663 | 0.88 | LMNA (0.59) | LMNANT5EHIF1AALDH1A1ALB | |
| SCHEMBL7435133 | 0.87 | LMNA (0.58) | LMNANT5EHIF1AALDH1A1ALB | |
| SCHEMBL4306006 | 0.87 | LMNA (0.55) | LMNANT5EHIF1AALDH1A1ALB | |
| SCHEMBL5548925 | 0.86 | LMNA (0.57) | LMNANT5EALDH1A1ALBMAPK1 | |
| SCHEMBL8124562 | 0.86 | LMNA (0.65) | LMNAALDH1A1ALBMAPK1CYP1A2 | |
| SCHEMBL9601706 | 0.86 | LMNA (0.57) | LMNAALDH1A1ALBMAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023178128-A1 | METHODS OF TREATING MEDICAL CONDITIONS USING ISLATRAVIR OR A RELATED COMPOUND | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2022256625-A1 | LINE-1 INHIBITORS AS COGNITIVE ENHANCERS | TRANSPOSON THERAPEUTICS, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2020263660-A1 | PROCESS FOR THE PREPARATION OF 2-FLUOROADENINE | MERCK SHARP & DOHME CORP. (US) | 2020-12-30 | — | — | WO | disclosed |
| US-RE45004-E1 | Bromo-phenyl substituted thiazolyl dihydropyrimidines | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-07-08 | — | — | US | disclosed |
| US-RE44987-E1 | Bromo-phenyl substituted thiazolyl dihydropyrimidines | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-07-01 | — | — | US | disclosed |
| EP-2514750-B1 | Bromo-phenyl substituted thiazolyl dihydropyrimidines | SUNSHINE LAKE PHARMA CO LTD (CN) | 2013-11-20 | — | — | EP | disclosed |
| US-8343969-B2 | Bromo-phenyl substituted thiazolyl dihydropyrimidines | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2013-01-01 | — | — | US | disclosed |
| US-20120282221-A1 | BROMO-PHENYL SUBSTITUTED THIAZOLYL DIHYDROPYRIMIDINES | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2012-11-08 | — | — | US | disclosed |
| EP-2514750-A1 | Bromo-phenyl substituted thiazolyl dihydropyrimidines | Sunshine Lake Pharma Co., Ltd (CN) | 2012-10-24 | — | — | EP | disclosed |
| EP-1286974-A2 | MEDICAMENT FOR VIRAL DISEASES | Bayer Aktiengesellschaft (DE) | 2003-03-05 | — | — | EP | disclosed |
| EP-1265889-A1 | MEDICAMENTS AGAINST VIRAL DISEASES | Bayer Aktiengesellschaft (DE) | 2002-12-18 | — | — | EP | disclosed |
| US-20020082264-A1 | Medicaments for viral diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2002-06-27 | — | — | US | disclosed |
| WO-2002020509-A2 | MEDICAMENTS AGAINST VIRAL INFECTIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-14 | — | — | WO | disclosed |
| WO-2001068640-A1 | MEDICAMENTS AGAINST VIRAL DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001068641-A1 | 6-AMINOALKYL-DIHYDROPYRIMIDINES AND THE USE THEREOF AS MEDICAMENTS AGAINST VIRAL DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001068642-A1 | DIHYDROPYRIMIDINES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001068647-A1 | MEDICAMENTS AGAINST VIRAL DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001068639-A1 | DIHYDROPYRIMIDINE-5-CARBOXYLIC ACID ESTERS AND USE THEREOF AS MEDICAMENTS AGAINST VIRAL DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001064755-A2 | ISOXAZOLE GEGEN VIRALE ERKRANKUNGEN | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082264-A1 | Medicaments for viral diseases | IRF3, STING1, EIF2AK2 | LMNA 2034/4885NT5E 2853/4885HIF1A 1182/4885 |
| US-20120282221-A1 | BROMO-PHENYL SUBSTITUTED THIAZOLYL DIHYDROPYRIMIDINES | HAVCR2, BRPF3, TYMP | LMNA 4391/4885NT5E 834/4885HIF1A 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.